Oruka Therapeutics, Inc. $ORKA Shares Purchased by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC increased its stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 10.7% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 603,479 shares of the company’s stock after purchasing an additional 58,117 shares during the period. Affinity Asset Advisors LLC owned 1.61% of Oruka Therapeutics worth $6,765,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of ORKA. Legal & General Group Plc purchased a new position in shares of Oruka Therapeutics in the second quarter worth $28,000. Ameritas Investment Partners Inc. acquired a new position in shares of Oruka Therapeutics in the 2nd quarter valued at $31,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Oruka Therapeutics in the 2nd quarter valued at $68,000. New York State Common Retirement Fund purchased a new position in Oruka Therapeutics in the 2nd quarter worth $96,000. Finally, Intech Investment Management LLC acquired a new stake in Oruka Therapeutics during the 2nd quarter worth about $168,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Wall Street Analysts Forecast Growth

ORKA has been the topic of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Wednesday, October 8th. Wedbush reiterated an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 12th. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. HC Wainwright decreased their price objective on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, October 27th. Finally, Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a research note on Thursday, November 13th. They issued a “buy” rating and a $45.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $45.14.

Oruka Therapeutics Stock Down 0.3%

Shares of Oruka Therapeutics stock opened at $30.84 on Friday. Oruka Therapeutics, Inc. has a twelve month low of $5.49 and a twelve month high of $31.80. The business has a 50-day moving average price of $26.62 and a 200 day moving average price of $18.20. The firm has a market cap of $1.49 billion, a PE ratio of -16.23 and a beta of -0.41.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. On average, sell-side analysts expect that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.